TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Apr 14, 2021 13:49 JST
Source:
Eisai
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at the Virtual American Academy of Neurology (AAN 2021) Annual Meeting from April 17 to 22, 2021.
As major presentations, an oral presentation regarding lecanemab will be given on the preliminary analysis for results of changes in brain-A beta levels and amyloid-related imaging abnormalities-edema (ARIA-E) as observed in subjects of the ongoing open-label extension of the Phase II study (Study 201) for early Alzheimer's disease (AD) patients. Poster presentations regarding lemborexant are also planned, including the results of a pilot study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment. Additionally, for perampanel, a global pooled analysis results from the real-world experiences including early adjunctive use or monotherapy will be presented at poster sessions.
Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with the disease and their families.
For more information, visit
https://www.eisai.com/news/2021/news202127.html
.
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
More Press release >>
Latest Press Release
Fujitsu automates entire software development lifecycle with new AI-Driven Software Development Platform
Feb 17, 2026 12:21 JST
Snow master Evans leads 1-2-3-4 finish for TGR-WRT
Feb 16, 2026 15:24 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 16, 2026 14:03 JST
Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026
Feb 13, 2026 22:50 JST
Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026
Feb 13, 2026 22:33 JST
Mitsubishi Power Hosts Inaugural Energy Forward Forum in Indonesia with Government and Industry Experts
Feb 13, 2026 22:24 JST
MHI Successfully Demonstrates Production of Liquid Synthetic Fuels through an integrated Process Utilizing SOEC Co-Electrolysis and FT Synthesis
Feb 13, 2026 22:03 JST
JCB Sponsors the NHK Symphony Orchestra Singapore Concert 2026 - Celebrating 60 Years of Singapore-Japan Relations
Feb 13, 2026 14:00 JST
Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense
Feb 12, 2026 19:59 JST
Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk
Feb 12, 2026 16:09 JST
Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty
Feb 12, 2026 12:13 JST
Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST
Honda Works Partner Aston Martin Aramco Formula One(TM) Team Unveils Livery of "AMR26" F1(TM) Machine Equipped with Honda Power Unit Ahead of the 2026 Race Season
Feb 10, 2026 18:25 JST
Honda to Make Organizational Changes to Further Enhance Competitiveness its Motorcycle, Automobile and Power Products Business
Feb 10, 2026 17:53 JST
KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System
Feb 10, 2026 14:15 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 10, 2026 13:34 JST
NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition
Feb 09, 2026 21:18 JST
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence
Feb 09, 2026 14:28 JST
JCB Announces Collaboration with Resorts World Sentosa in Singapore
Feb 09, 2026 14:00 JST
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Feb 09, 2026 11:00 JST
More Latest Release >>